No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MTEM Molecular Templates
- 1.7050
- +0.1050+6.56%
Close Apr 26 16:00 ET
- 1.7000
- -0.0050-0.29%
Post 18:02 ET
11.23MMarket Cap-947P/E (TTM)
1.7400High1.5142Low69.21KVolume1.6200Open1.6000Pre Close112.96KTurnover1.54%Turnover RatioLossP/E (Static)6.58MShares9.450052wk High2.66P/B7.65MFloat Cap1.400052wk Low--Dividend TTM4.48MShs Float16810.1847Historical High--Div YieldTTM14.11%Amplitude1.4000Historical Low1.6320Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Molecular Templates Inc Files For Shelf Of Up To 11.01M Shares Of Common Stock By Selling Stockholders
Express News | Molecular Templates Inc Files for Shelf of up to 11.01 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Molecular Templates to Cut 30% of Staff, Chief Medical Officer
By Ben Glickman Molecular Templates said it would lay off about 30% of its workforce and cut its chief medical officer as it looks to stretch its resources. The Austin, Texas-based biopharmaceutical
Express News | Molecular Templates Inc Estimates That It Will Incur Aggregate Pre-Tax Charges Of ~$0.1M In Connection With Reduction In Force; Effective April 30; Reduction To Extend Resources To Allow Co To Continue To Support Clinical Studies For MT-6402, MT-8421 And
Express News | Molecular Templates Inc Says Reduction In Force Would Reduce Company's Current Workforce By ~30%; Approved A Reduction In Force; Expects That Reduction In Force Will Be Complete By End Of April 2024
Express News | Molecular Templates: Reduction to Extend Resources to Allow Co to Continue to Support Clinical Studies for Mt-6402, Mt-8421 and Mt-0169
Comments
$9.5 Million Private Placement Offering Secured By Biotechnology Company
Molecular Templates Secures $9.5 Million Through Private Placement: How It Affects You.
In a significant development that underscores the dynamic nature of the biotechnology industry, Molecular Templates, Inc. (MTEM), a pioneer in the field of engineered toxin bodies (ETBs) for cancer therapy, has announced a major financial milestone. The company has successfully secured a $9.5 million private placement offering, a move tha...
In a significant development that underscores the dynamic nature of the biotechnology industry, Molecular Templates, Inc. (MTEM), a pioneer in the field of engineered toxin bodies (ETBs) for cancer therapy, has announced a major financial milestone. The company has successfully secured a $9.5 million private placement offering, a move tha...
1
Given Molecular Templates' shrinking revenue forecast, its low P/S ratio is justified, particularly against the industry's high growth projections. A big change appears needed for a substantial stock price rise.
Molecular Templates' low P/S ratio mirrors industry peers despite poor growth outlook, which could stagnate stock price. Also, the company has 5 warning signs creating further risk for investors.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg